Avalo Therapeutics (AVTX) Competitors $10.88 -0.14 (-1.27%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$10.76 -0.13 (-1.15%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. ALMS, CMPX, TECX, KOD, ETON, ARCT, RGNX, ITOS, ESPR, and CGEMShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Alumis (ALMS), Compass Therapeutics (CMPX), Tectonic Therapeutic (TECX), Kodiak Sciences (KOD), Eton Pharmaceuticals (ETON), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), Esperion Therapeutics (ESPR), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Its Competitors Alumis Compass Therapeutics Tectonic Therapeutic Kodiak Sciences Eton Pharmaceuticals Arcturus Therapeutics REGENXBIO iTeos Therapeutics Esperion Therapeutics Cullinan Therapeutics Avalo Therapeutics (NASDAQ:AVTX) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Which has more volatility & risk, AVTX or ALMS? Avalo Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Alumis has a beta of -1.38, suggesting that its share price is 238% less volatile than the S&P 500. Which has preferable earnings & valuation, AVTX or ALMS? Avalo Therapeutics has higher revenue and earnings than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K325.16-$35.13MN/AN/AAlumisN/AN/A-$294.23MN/AN/A Do insiders and institutionals have more ownership in AVTX or ALMS? 87.1% of Avalo Therapeutics shares are held by institutional investors. 3.0% of Avalo Therapeutics shares are held by insiders. Comparatively, 40.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to AVTX or ALMS? In the previous week, Avalo Therapeutics had 4 more articles in the media than Alumis. MarketBeat recorded 7 mentions for Avalo Therapeutics and 3 mentions for Alumis. Alumis' average media sentiment score of 1.19 beat Avalo Therapeutics' score of 1.08 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend AVTX or ALMS? Avalo Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 175.74%. Alumis has a consensus price target of $20.17, indicating a potential upside of 362.54%. Given Alumis' stronger consensus rating and higher possible upside, analysts plainly believe Alumis is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is AVTX or ALMS more profitable? Avalo Therapeutics' return on equity of -48.48% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -48.48% -35.94% Alumis N/A -119.15%-92.50% SummaryAvalo Therapeutics beats Alumis on 8 of the 13 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$144.94M$2.55B$5.78B$10.07BDividend YieldN/A56.65%5.69%4.62%P/E RatioN/A23.7674.9726.20Price / Sales325.16564.68472.3091.87Price / CashN/A169.2537.0859.91Price / Book0.855.3912.116.28Net Income-$35.13M$32.95M$3.29B$270.85M7 Day Performance-6.21%2.61%1.55%3.58%1 Month Performance16.24%9.87%7.83%6.67%1 Year Performance21.02%1.49%61.70%27.73% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.8216 of 5 stars$10.88-1.3%$30.00+175.7%+32.7%$144.94M$440K0.0040Positive NewsShort Interest ↓ALMSAlumis3.3578 of 5 stars$4.64-1.3%$20.17+334.6%-60.1%$482.86MN/A0.00N/ACMPXCompass Therapeutics2.5098 of 5 stars$3.49flat$12.89+269.3%+135.3%$482.61M$850K-7.7620Positive NewsTECXTectonic Therapeutic3.2512 of 5 stars$25.54-0.1%$80.33+214.5%+3.0%$477.91MN/A-6.32120Positive NewsKODKodiak Sciences3.611 of 5 stars$9.04+0.8%$11.75+30.0%+301.6%$477.51MN/A-2.3890ETONEton Pharmaceuticals2.0115 of 5 stars$17.31+0.2%$29.67+71.4%+266.8%$464.21M$39.01M-108.1920Positive NewsARCTArcturus Therapeutics3.0073 of 5 stars$17.01-1.7%$50.57+197.3%-14.0%$461.90M$152.31M-7.63180Positive NewsRGNXREGENXBIO4.6172 of 5 stars$8.93-0.9%$28.38+217.7%-25.3%$451.09M$83.33M-2.60370ITOSiTeos Therapeutics3.4394 of 5 stars$10.15flat$15.50+52.7%N/A$448.68M$35M-2.1790Positive NewsESPREsperion Therapeutics4.1364 of 5 stars$2.22+0.5%$7.00+215.3%+60.3%$447.60M$332.31M-4.53200Positive NewsCGEMCullinan Therapeutics2.4688 of 5 stars$7.54-0.9%$26.80+255.4%-63.2%$445.42MN/A-2.3330Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Alumis Competitors Compass Therapeutics Competitors Tectonic Therapeutic Competitors Kodiak Sciences Competitors Eton Pharmaceuticals Competitors Arcturus Therapeutics Competitors REGENXBIO Competitors iTeos Therapeutics Competitors Esperion Therapeutics Competitors Cullinan Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTX Stock Alerts